Investment Research and Business Due Diligence
Sunday, September 15, 2013
Sanofi re launches OTC heart burn drug Rolaids after 3 years in the US market
Sanofi US and its consumer health business Chattem, Inc., have re-introduced Rolaids® to stores across the United States. The iconic brand returns after a three-year hiatus in the marketplace and follows Chattem’s acquisition of Rolaids earlier this year.
Rolaids is sold in retail stores across the United States and is available in both tablets and a new
liquid form. The liquid is a first for the brand, as is new Ultra Strength formulation in both tablets and
liquid. Ultra Strength Tablets and Liquid deliver Rolaids' strongest level of acid neutralization.
Chattem completed the acquisition of the worldwide rights to the Rolaids brand from McNeil
Consumer Healthcare Division of McNEIL-PPC, Inc. on January 7, 2013.
Enter your email address:
Share to Twitter
Share to Facebook
Share to Pinterest
Post Comments (Atom)